TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05624138
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of modified FOLFOX-6 regimen (Oxaliplatin, Fluorouracil, calcium leucovorin) with 2 mg placebo tablets
Study: NCT05566288
Drug: Cytisinicline
Normalized name: cytisinicline
Approvals — FDA: no, EMA: no, PMDA: no
Description: compressed film-coated tablet containing 3 mg cytisinicline
Study: NCT05566288
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets to match compressed film-coated tablet containing 3 mg cytisinicline
Study: NCT05723458
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream containing vaseline
Study: NCT04578015
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in this arm will receive placebo
Study: NCT05066633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be in the form of identical tablets and will be administered orally once daily.
Study: NCT06000956
Drug: Jitongning tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.
Study: NCT06642571
Drug: NNC0519-0130 B
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0519-0130 B will be administered subcutaneously.
Study: NCT05129761
Drug: Syrup Hydryllin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
Study: NCT05996380
Drug: SHR-3167 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-3167 Placebo Single administration
Study: NCT05456152
Drug: Sublingual Tablet
Normalized name: Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual zolpidem - 1 sublingual tablet 30 minutes before bed time.
Study: NCT00286364
Drug: Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05966493
Drug: lufepirsen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lufepirsen is an unmodified connexin43 antisense oligonucleotide.
Study: NCT05966493
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching vehicle without lufepirsen.
Study: NCT05017714
Drug: Recombinant cytokine gene derived protein injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized Novaferon, given 20 ug BID, daily for 7 days, plus Standard of Care.~Inhaled Saline (placebo), given BID, daily for 7 days, plus Standard of Care.
Study: NCT06122987
Drug: Angiotensin II and hydrocortisone sodium succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion angiotensin II (titrated for each individual patient by effect) and hydrocortisone 50 mg intravenous bolus every 6 hours.
Study: NCT05511025
Drug: AZD6234
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single dose of AZD6234 as a solution via SC or IV injection
Study: NCT05511025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching volumes of the placebo as a solution via SC or IV injection
Study: NCT06553846
Drug: Lutetium [177Lu]-FAP-75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutetium \[177Lu\]-FAP-75 will be administrated per dose level in which the patients are assigned.
Study: NCT05424887
Drug: AK3280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT05424887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral
Study: NCT06299813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo used in the study will consist of 100 ml of purified water (PPI BBU).
Study: NCT05466734
Drug: PMR Tablet 135 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose (total daily dose of 270 mg)
Study: NCT00264446
Drug: ADH300004
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06052293
Drug: ANG003
Approvals — FDA: no, EMA: no, PMDA: no
Description: To evaluate four possible combinations of lipase, protease and amylase.
Study: NCT05778461
Drug: L-ornithine L-Aspartate
Normalized name: L-ornithine L-aspartate
Approvals — FDA: no, EMA: no, PMDA: no
Description: LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
Study: NCT05778461
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered via continuous infusion for 72h, along with HVPE (2x plasma volume) starting at 8h, 32h and 56h respectively.
Study: NCT04751487
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe Route of administration: subcutaneous
Study: NCT04996979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care
Study: NCT06384833
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin C (solution) 500 mg IV q4h for 4 doses PO d0 Vitamin C (tablet) 100mg 5 tab PO BID for 45 days
Study: NCT06007235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline solution in identical spray bottles
Study: NCT06191289
Drug: Transdermal Estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg/24hr transdermal estradiol for 14 days starting day 7 after positive urine luteinizing hormone test~Other Names:~Climara
Study: NCT06531278
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Patients are planned to receive fluorouracil (2400mg/m2; d1) of every cycle.~* 27 days a cycle
Study: NCT05005052
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and no compression or venopharmaceutical regimen
Study: NCT05032781
Drug: Intra-arterial cold saline, minocycline, and magnesium
Approvals — FDA: no, EMA: no, PMDA: no
Description: See study design
Study: NCT05697614
Drug: Phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: phenytoin is used for both general or focal epilepsy in case valproic acid or carbamazepine is contraindicated, used in experimental group
Study: NCT05697614
Drug: Oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oxcarbazepine is used for focal type epilepsy, used in control group
Study: NCT01101412
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given through CVC or PVC
Study: NCT06081478
Drug: CD19/CD22-bispecific CAR-T cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19/CD22-bispecific CAR-T cells were infused at the same day with 2×10e6/kg and 1×10e6/kg dosage, respectively.
Study: NCT04795037
Drug: CU06-1004, Single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of CU06-1004, 7 dose levels, oral capsule : 6 Cohorts (100mg, 300mg, 600mg, 900mg, 1200mg, 300mg bid) + 1 Cohort (Food effect)＊~＊Cohort S7(TBD mg) will receive a single oral dose of CU06-1004 or placebo under fed conditions. When administered under fed conditions, CU06-1004 or placebo will be administered following a high-fat/high-calorie breakfast. Cohort S7 will be conducted following completion of Cohort S5
Study: NCT04795037
Drug: CU06-1004, Multiple doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses of CU06-1004, 7 days, 3 dose levels＊, oral capsule~＊The dose levels, regimen (i.e., schedule), and conditions (i.e., fasted versus fed conditions) will be determined based on the safety, tolerability, and plasma PK data from SAD
Study: NCT04975711
Drug: HIP2105
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test drug
Study: NCT04975711
Drug: RLD2104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference drug
Study: NCT05680584
Drug: Melatonin 3 MG
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.1 mg/ kg melatonin in 10 ml apple juice 1 hour before induction of anesthesia
Study: NCT06054035
Drug: Placebo matching Dapaglifolzin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching Dapaglifolzin once daily for 2 years. Route of administration: oral.
Study: NCT04807920
Drug: OnabotulinumtoxinA 100 UNT
Normalized name: onabotulinumtoxinA 100 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical injection
Study: NCT05117346
Drug: CARDIX-101A, CARDIX-101B, CARDIX-101C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will receive, via oral administration, one capsule of study medicine per dose and three doses per day for 14±2-days treatment.
Study: NCT05044117
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine (650 mg/m2 bid, d1-21, q3w) for 1 year
Study: NCT04975204
Drug: TQB3909 Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB3909 is an inhibitor targeting BCL-2 protein
Study: NCT05924412
Drug: Intravenous study drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg parecoxib will be administered intravenously after general anesthesia induction and before tourniquet inflation and surgical incisión
Study: NCT05305066
Drug: TNFi
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFi - any sub-cutaneous (sc) formulation, namely etanercept (receptor fusion protein) 50 mg sc per week, adalimumab (monoclonal antibody) 40 mg sc every 2 weeks, golimumab (monoclonal antibody) 50 mg sc every month, or certolizumab (pegylated fragment of a monoclonal antibody) 400 mg sc at week 0, 2 and 4, and then 200 mg sc every 2 weeks or 400 mg sc every 4 weeks.
Study: NCT05305066
Drug: JAKi
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAKi - tofacitinib (JAK1/3 inhibitor) 5 mg po bid, baricitinib 2 mg po qd (JAK 1/2 inhibitor) or upadacitinib 15 mg po qd (JAK1 inhibitor)
Study: NCT05806996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equivalent volume of normal saline
Study: NCT06045013
Drug: 5% dextrose injections with methylprednisolone acetate 40 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single ultrasound-guided injection of 3 ml 5% dextrose with 1 ml 40 mg/ml methylprednisolone acetate in carpal tunnel via ulnar approach.
Study: NCT05924321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of matching placebo
Study: NCT04789837
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet twice daily plus Celecoxib 200mg capsule
Study: NCT06531837
Drug: Remifentanil (Target-Controlled Infusion)
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The plasma drug concentrations of remifentanil were set at 0.5 ng/ml, 1 ng/ml, and 1.5 ng/ml. After each plasma drug concentration reached a steady state, the NRS scores were assessed, and resting-state EEG was recorded for at least 5 minutes.
Study: NCT06531837
Drug: Flurbiprofen (Single intravenous injection)
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single intravenous injection of Flurbiprofen at a dose of 100 mg. Collect resting-state EEG data and NRS scores 10 minutes after administration.
Study: NCT06326346
Drug: Liporaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liporaxel 200mg/m2 twice daily orally on day 1, 8, and 15 every 4 weeks (1 cycle = 4 weeks)
Study: NCT05037825
Drug: Checkpoint Inhibitor, Immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD-1, anti-PD-L1, or anti-CTLA-4 as a single agent or in combination with another checkpoint inhibitor or other treatment agent or modality (e.g., targeted therapy, chemotherapy, surgery, radiation, etc.) in accordance with FDA-labeled use of the agent
Study: NCT04859452
Drug: Simvastatin tablets
Normalized name: Simvastatin Tablets
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: Simvastatin, tablet, oral
Study: NCT05310071
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm.
Study: NCT00000714
Drug: Leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05883124
Drug: Exelon® 9.5 mg/24 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period
Study: NCT05317312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet
Study: NCT06361680
Drug: Coenzyme Q10 Cap/Tab as natural factors capsules or kirkman tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A will take Soft gel capsules or tablets of Coenzyme Q10 in a dose of 100-200mg of natural factors or kirkman but group B will not take Coenzyme Q10 just observe them
Study: NCT05533619
Drug: Proton pump inhibitor
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatients using proton pump inhibitor
Study: NCT05807490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as oral suspensions BID over 14 days
Study: NCT05807490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as oral suspensions QD over 14 days
Study: NCT05807490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days
Study: NCT05807490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Study: NCT05293119
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone furoate 0.1% ointment once daily
Study: NCT04617457
Drug: nal-irinotecan (nal-iri) (Onyvide), oxaliplatin (ox), 5-fluouracil (5-FU), folinic acid (FA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: preoperative chemotherapy
Study: NCT06372210
Drug: Placebo IEM tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo-embedded IEM tablet.
Study: NCT06372210
Drug: Abilify MyCite®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aripiprazole-embedded IEM tablet.
Study: NCT04728802
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill
Study: NCT05782777
Drug: high-intensity statin monotherapy (atoravastatin 40mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of lipid-lowering therapy will be atoravastatin 40mg. During follow-up, the dose of atoravastatin 40mg is strongly recommended to be maintained.
Study: NCT06517914
Drug: YH35995
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of YH35995
Study: NCT06517914
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of Placebo
Study: NCT00002100
Drug: Curdlan sulfate
Normalized name: curdlan
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05582798
Drug: Alpha 1-Proteinase Inhibitor 180mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha1-proteinase inhibitor (human) intravenous infusion
Study: NCT05582798
Drug: Alpha 1-Proteinase Inhibitor 120mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha1-proteinase inhibitor (human) intravenous infusion
Study: NCT05888857
Drug: MEDI5752
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment cycle consists of 3 weeks. MEDI5752 will be administered by intravenous infusion at a fixed dose on Day 1 of each cycle
Study: NCT00115414
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00115414
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06239727
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic adjuvant capecitabine chemotherapy: 650 mg/m2 p.o. bid, 1 year, adminstration starts immediately after concurrent chemoradiotherapy.
Study: NCT05192239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercially available non-THC fruit snack
Study: NCT05138861
Drug: TP-03 (Lotilaner Ophthalmic Solution), 0.25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.
Study: NCT04564092
Drug: DaTSCAN™ Ioflupane (123I) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each participant will receive a single administration of DaTSCAN™ ioflupane (123I) injection by bolus IV injection with a nominal iodine (123I) activity of 111 MBq ±10%, in a maximum volume of 5 mL.
Study: NCT05344495
Drug: hyalase group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.
Study: NCT05702983
Drug: STSA-1002 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single low dose on day 1 following protocol requirements.
Study: NCT05702983
Drug: STSA-1002 subcutaneous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single high dose on day 1 following protocol requirements.
Study: NCT05894707
Drug: SCT650C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant anti-IL-17A antibody
Study: NCT05839314
Drug: Huaier granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huaier granule, oral administration, 10g each time, 3 times a day, continuous medication for 24 weeks. After 24 weeks of treatment, the dosage should be adjusted according to efficacy.
Study: NCT05839314
Drug: Ciclosporin soft capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of Ciclosporin soft capsules is an oral dose of 3.5mg/kg/d, divided into two equal doses, given every 12 hours. Assess the plasma concentration of CsA (valley value) every 2 weeks in the first 8 weeks. If the plasma concentration of CsA reaches 100-150ug/L, continue to maintain the dose. If the plasma concentration of CsA is below the target concentration, increase the dose of CsA. If the plasma concentration of CsA is higher than the upper limit of the target concentration, appropriate dose reduction. A single dose adjustment is 25mg/d. After increasing/decreasing the dose, CsA concentration is remeasured at intervals of 2 weeks ±3 days until the target concentration is reached.~CsA at target concentration followed by 24 weeks of treatment, then the dosage shall be adjusted according to efficacy.
Study: NCT05674825
Drug: Targeted agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: The Molecular Tumor Board (MTB) will suggest molecularly targeted matched treatment.
Study: NCT05674825
Drug: Standard of care agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive treating physician's choice of traditional systemic therapy treatment for their malignancy, defined by National Comprehensive Cancer Network (NCCN) guidelines and/or tumor board recommendation(s).
Study: NCT05580250
Drug: LY3526318
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05580250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05580250
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05881837
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection: dose level 1 for 32 weeks、level 2 for 20 weeks
Study: NCT05881837
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection: dose level 2
Study: NCT05881837
Drug: HRS9531 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRS9531 injection: dose level 3
Study: NCT05881837
Drug: HRS9531 injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm matching active arm HRS9531 injection dose level 1 for 32 weeks、HRS9531 injection level 2 for 20 weeks
Study: NCT05881837
Drug: HRS9531 injection Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo arm matching active arm HRS9531 injection dose level 4 for 32 weeks、HRS9531 injection level 2 for 20 weeks
Study: NCT05422001
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic Saline
Study: NCT06353347
Drug: HTD1801
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTD1801 1000 mg administered orally BID as four capsules
Study: NCT06353347
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered orally BID as four capsules
Study: NCT03527069
Drug: Cipros 10 association
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, once a day.
Study: NCT06361927
Drug: SSGJ-707
Approvals — FDA: no, EMA: no, PMDA: no
Description: bispecific antibody
Study: NCT06265454
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT05157412
Drug: Doxycycline 100 mg Oral Tablet
Normalized name: DOXYCYCLINE 100 mg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Doxycycline will be added to prednisolone as a comparison to using prednisolone as a sole therapy for the treatment of nasal polyps associated with chronic rhinosinusitis
Study: NCT05157412
Drug: Prednisolone 20 mg
Normalized name: prednisolone 20 MG
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone will be used in both arms as a sole therapy in one and together with doxycycline in the other
Study: NCT06020911
Drug: Biodentine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 primary second molars of 17 children will be capped with Biodentine
Study: NCT05059873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo of 40mg/day for five consecutive days
Study: NCT05966584
Drug: fulvestrant or AIs) and PI3K inhibition (alpelisib)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)